STP Bay Area Regional Meeting & Webinar Presentation—December 6, 2019
STP Bay Area Regional Meeting December 6, 2019
"Mouse Models in Drug Development"
Genentech, Building 40 600 East Grand Avenue South San Francisco, CA
You are invited to join your colleagues for a day-long STP Bay Area Regional Meeting entitled "Mouse Models in Drug Development" to be held on December 6, 2019 at Genentech, Inc., in South San Francisco, CA. There is no fee to attend, however, registration is required by December 2, and we encourage you to register early as space is limited. This one-day meeting is sponsored by Genentech and includes lunch for registered attendees.
The presentation by Dr. James Turk will be available as a webinar at 1:00 PM PST / 4:00 PM EST. See below for registration details. There is no deadline to register for the webinar.
Thank you to Genentech, Inc. for the generous contribution towards this event.
Title: Morphological and Transcriptional Endpoints in Apolipoprotein-E Knockout Mouse Models of Atheroprogression: Examination of Plausible Mechanisms of Cardiovascular Adverse Events Date/Time: December 6, 2019 | 4:00 PM–4:45 PM EST Speaker: James R. Turk, DVM, PhD, DACVP Abstract: Atherosclerosis is a uniquely human disease. No animal model recapitulates the morphological features of human atherosclerotic plaques with progression to the manifestation of ischemic disease. However, the mouse has been reported to be the best model species for mechanistic studies, and the Apolipoprotein-E knockout (apoE-KO) mouse is the most commonly used animal model of human atherosclerosis. In addition, translationally relevant imaging such as microCT can be used in mice to assess atheroprogression or regression.
While the mouse model may not faithfully reproduce human atherosclerotic plaque morphology, the ApoE KO mouse does effectively capture putative pathophysiological mechanisms underpinning human plaque development at the transcriptional signaling pathway level.
We examined two mouse models to assess putative pathways underpinning acute coronary syndromes. (1) The high fat diet fed ApoE KO ovariectomized mouse model was selected because the high-fat diet ApoE mouse is a widely used model for atherosclerosis, and the OVX mouse is a widely used model for postmenopausal osteoporosis. OVX also accelerates aortic lesion development and plaque calcification. (2) The angiotensin II-infused male ApoE KO model was selected because it was the model in which sclerostin overexpression was reported to inhibit atheroprogression and systemic inflammation.
Approximately 70% of the differentially regulated pathways reported in human carotid artery plaques compared to normal artery were significantly changed in at least one timepoint in either of our two murine models with the most significant pathways in human preserved in both models. These preserved pathways included pathways related to inflammation, immunity and atherosclerosis. Speaker Bio: James R. Turk completed a BA in Biology at Washington University, St. Louis, MO; DVM at the University of Missouri in Columbia, MO; PhD at Washington State University; and Pathology Residency at Washington Animal Disease Diagnostic Laboratory in Pullman, WA. He is certified in anatomic pathology by the American College of Veterinary Pathologists. Jim was Assistant and Associate Professor at Louisiana State University, Baton Rouge, LA; and is Professor Emeritus of Biomedical Sciences and Pathology, University of Missouri Columbia. Jim has won numerous awards for teaching professional and graduate students, including 2 Norden Awards for Distinguished Teaching in Veterinary Medicine, performed many years of diagnostic service, and award-winning research in cardiovascular disease funded by the National Heart Lung and Blood Institute. Jim has worked as a Pathologist at Merck in West Point, PA, and Pfizer, St. Louis, MO, and since 2008 has been a Pathology Director at Amgen, Thousand, Oaks, CA in the Department of Comparative Biology and Safety Sciences. He is currently Functional Group Lead: Translational Cardiovascular Pathology and Biomarkers in the Safety Pharmacology and Animal Research Center.